Sporet levering verden over | Forventet 9–14 hverdage

Din kurv

Din indkøbskurv er tom

Begynd at browse

Gratis fragt på ordrer over €500.

Subtotal€0
Gå til betaling
HudGodkendt lægemiddel

Melanotan 2

Publiceret forskning og dokumentationsgrundlag

Melanotan II and afamelanotide are synthetic analogues of alpha-melanocyte-stimulating hormone that act at melanocortin receptors to increase eumelanin synthesis. Afamelanotide (a selective, largely MC1R-directed analogue) is an approved medicine for erythropoietic protoporphyria supported by randomised placebo-controlled trials and post-authorisation safety cohorts, and has been trialled with narrowband UV-B in vitiligo. Melanotan II is a non-selective, unlicensed peptide sold illegally for tanning; it has never been through a completed efficacy or safety programme; beyond a 1996 pilot study and two small placebo-controlled crossover trials in erectile dysfunction (1998 and 2000), its published human literature consists mainly of adverse-event case reports, including eruptive and dysplastic naevi, melanoma and mucosal melanoma, priapism, renal infarction and systemic reactions.

Kort fortalt
  • Melanotan II er et syntetisk analogon af alpha-melanocytstimulerende hormon.
  • Humane forsøg testede det kun ved erektil dysfunktion i 1998 og 2000.
  • Intet kontrolleret forsøg findes for solbrænding og data kommer fra case reports.

36 studier · 13 siden 2023 · nyeste 2026

Undersøgelser citeret
36
Publiceret 2023+
13
Nyeste artikel
2026
Sidst gennemgået
okt. 2026

Tilbagevendende temaer i litteraturen

  • melanocortin 1 receptor agonism
  • eumelanin induction and photoprotection
  • erythropoietic protoporphyria phototoxicity
  • vitiligo repigmentation
  • eruptive and dysplastic melanocytic naevi
  • melanoma case reports
  • unregulated peptide supply and social media promotion
  • non-selective melanocortin receptor adverse effects

Stofidentifikatorer

CAS
121062-08-6
PubChem
92432

Kemisk identitet

Hvad Melanotan 2 er, kemisk.

Molekylformel
C50H69N15O9
Molekylvægt
1024.2 g/mol
CAS-nummer
121062-08-6
PubChem CID
92432
Også skrevet som

Melanotan II

Disse tal stammer fra PubChem-posten for denne forbindelse og beskriver den frie base. Lyofiliseret peptid leveres normalt som et acetat- eller trifluoroacetatsalt og indeholder restvand, så massen af pulver i et hætteglas er ikke den samme mængde, som molekylvægten ovenfor ville antyde. Kromatografisk renhed på et analysecertifikat løser heller ikke den forskel — Sådan læses et analysecertifikat forklarer hvorfor.

Evidensen

36 offentliggjorte studier.

Sorteret efter styrken i studiedesignet og derefter efter nyhed. Hver post linker til sin kildepost, så fundet kan kontrolleres mod artiklen i stedet for at tages på vores ord.

  1. 01Systematisk gennemgang2026

    Insights into Tanning Biology and Tanning Products.

    Resnick G, et al. · The Journal of Clinical and Aesthetic Dermatology · PRISMA systematic review of 68 peer-reviewed studies on dihydroxyacetone, melanotan, forskolin and carotenoids

    The review assessed mechanisms, clinical uses, formulations and adverse effects of self-tanning agents, covering melanotan alongside dihydroxyacetone, forskolin and carotenoids. It is the most recent systematic appraisal placing melanotan within the tanning-product landscape.

    Rapporteret sikkerhedsfund. Reviewed adverse effects of unregulated tanning agents including melanotan.

  2. 02Systematisk gennemgang2024

    A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.

    Jafarzadeh A, et al. · Skin Research and Technology · systematic review of case series and clinical trials of systemic oral and injectable vitiligo therapies

    The review placed afamelanotide among systemic injectable options for vitiligo alongside corticosteroids, immunosuppressants and other agents, and characterised the overall evidence base for systemic vitiligo therapy as limited and heterogeneous.

  3. 03Systematisk gennemgang2023

    Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: A systematic review.

    Heerfordt IM, et al. · Biomed Pharmacother · systematic review of 40 studies (13 controlled trials) on 18 treatments for photosensitivity in EPP and XLP, plus EMA/FDA safety data

    Controlled trials showed a moderate positive effect of afamelanotide implants and inorganic sunscreen, and no effect of organic sunscreen, beta-carotene, cysteine, N-acetylcysteine, vitamin C or warfarin. The authors noted a high risk of bias in photosensitivity outcomes.

  4. 04Humant klinisk2026

    Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

    Seidl-Philipp M, et al. · Journal der Deutschen Dermatologischen Gesellschaft · Austrian erythropoietic protoporphyria patient cohort treated with afamelanotide

    Afamelanotide treatment was associated with improved quality of life and light tolerance in an Austrian EPP cohort, adding a further national real-world dataset to the approved indication.

  5. 05Humant klinisk2025

    German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).

    Homey B, et al. · Photodermatology, Photoimmunology & Photomedicine · post-authorisation safety study (EUPAS13004), German arm of the European EPP Disease Registry, n=200 treated patients

    This regulator-mandated observational study collected short- and long-term safety and effectiveness data on afamelanotide 16 mg in treated EPP patients. It represents the structured pharmacovigilance that exists for the approved analogue and has no counterpart for melanotan II.

  6. 06Humant klinisk2024

    Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.

    Leaf RK, et al. · Life (Basel) · US cohort of patients with protoporphyria treated with afamelanotide

    The study examined quality-of-life change and laboratory parameters in US protoporphyria patients receiving afamelanotide, contributing observational rather than randomised evidence.

  7. 07Humant klinisk2023

    Dersimelagon in Erythropoietic Protoporphyrias.

    Balwani M, et al. · The New England Journal of Medicine · randomised placebo-controlled phase 2 trial, adults 18-75, placebo versus dersimelagon 100 mg or 300 mg once daily for 16 weeks

    Dersimelagon, an orally administered selective MC1R agonist that increases skin eumelanin, was assessed for time to onset and severity of symptoms after sunlight exposure in erythropoietic and X-linked protoporphyria. The trial demonstrates that MC1R agonism is being developed as a regulated oral drug class distinct from injectable tanning peptides.

  8. 08Humant klinisk2020

    Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.

    Wensink D, et al. · JAMA Dermatology · single-centre prospective post-authorisation safety and efficacy cohort, EMA-approved protocol, June 2016 to September 2018

    Afamelanotide treatment in routine practice was assessed for time spent outdoors, number of phototoxic reactions, disease-specific quality of life, use of protective clothing and adverse events. The study extended pivotal-trial findings into longer-term real-world follow-up.

  9. 09Humant klinisk2015

    Afamelanotide for Erythropoietic Protoporphyria.

    Langendonk JG, et al. · The New England Journal of Medicine · two multicentre randomised double-blind placebo-controlled trials of 16 mg subcutaneous implants; 74 patients (EU) and 94 patients (US)

    Patients received afamelanotide or placebo implants every 60 days and were assessed on duration of sun exposure, number and severity of phototoxic reactions and quality of life. These are the pivotal trials underpinning regulatory approval of afamelanotide for erythropoietic protoporphyria.

  10. 10Humant klinisk2015

    Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

    Lim HW, et al. · JAMA Dermatology · randomised multicentre trial, n=55 adults with non-segmental vitiligo (15-50% BSA), afamelanotide 16 mg implant plus NB-UV-B (n=28) versus NB-UV-B alone (n=27)

    Combination therapy with afamelanotide implants added to narrowband UV-B was compared with narrowband UV-B monotherapy in Fitzpatrick skin phototypes III to VI. This is the principal randomised evidence for a melanocortin analogue in vitiligo.

  11. 11Humant klinisk2000

    Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.

    Wessells H, et al. · Urology · double-blind placebo-controlled crossover RCT, n=10 men with erectile dysfunction and organic risk factors

    Melanotan II initiated erections after 12 of 19 injections versus 1 of 21 placebo doses, and sexual desire scores were higher than after placebo. Nausea and stretching/yawning were more frequent, and 4 of 19 injections were followed by severe nausea.

    Rapporteret sikkerhedsfund. Severe nausea followed 4 of 19 melanotan II injections.

  12. 12Humant klinisk1998

    Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.

    Wessells H, et al. · J Urol · double-blind placebo-controlled crossover trial, n=10 men with psychogenic erectile dysfunction, RigiScan monitoring

    Clinically apparent erections developed in 8 of 10 men after melanotan II; mean duration of tip rigidity above 80% was 38.0 minutes versus 3.0 minutes with placebo. Nausea, stretching and yawning, and decreased appetite were reported more often with melanotan II.

  13. 13Humant klinisk1996

    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.

    Dorr RT, et al. · Life Sci · pilot phase 1 single-blind placebo-controlled alternating-day study, n=3 healthy men, 2 weeks

    Melanotan II increased pigmentation of the face, upper body and buttock in two subjects, measured by reflectance one week after dosing ended. Mild nausea occurred at most dose levels, one subject had grade II somnolence and fatigue, and a stretching and yawning complex accompanied spontaneous penile erections lasting 1-5 hours.

    Rapporteret sikkerhedsfund. Spontaneous erections, nausea, somnolence and fatigue were observed in the first human study of melanotan II.

  14. 14In vitro2015

    Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.

    Breindahl T, et al. · Drug Test Anal · validated LC-UV-MS/MS analysis of injectable melanotan II vials bought from three online shops

    All vials were labelled as 10 mg, but measured melanotan II content ranged from 4.32 to 8.84 mg. Vials from two shops contained 4.1-5.9% unknown impurities.

    Rapporteret sikkerhedsfund. Internet-sold melanotan II vials were under-filled and contained unidentified impurities.

  15. 15Gennemgang2026

    Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks.

    Sidhu AS, et al. · International Journal of Dermatology · correspondence on social-media promotion of unregulated melanotan

    The letter framed social-media-driven melanotan use as an emerging dermatological and public health risk. The PubMed record carries no abstract.

    Rapporteret sikkerhedsfund. Social-media promotion identified as a driver of unregulated melanotan exposure.

  16. 16Gennemgang2021

    Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

    Gilhooley E, et al. · Dermatology · retrospective qualitative analysis of UK and Ireland online chatrooms and forums, January 2016 to October 2017

    The study characterised motivations for melanotan II use and self-reported side effects from user forums, and noted that the covert nature of supply makes population-level prevalence and adverse-event rates difficult to establish.

    Rapporteret sikkerhedsfund. Self-reported side effects catalogued from user communities; true adverse-event incidence is unmeasurable because supply is unregulated.

  17. 17Gennemgang2017

    Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.

    Habbema L, et al. · International Journal of Dermatology · narrative review of unregulated melanotan I and II use compared with approved afamelanotide

    The review concluded that although afamelanotide has been thoroughly tested and deemed safe for its licensed indications, illegally supplied melanotans carry risks arising from unknown preparation, administration and dosage, and that case reports of adverse events following unregulated melanotan use were increasing.

    Rapporteret sikkerhedsfund. Unregulated melanotan I and II preparations are of unknown purity, dose and sterility; a growing case-report literature documents dermatological and systemic harms.

  18. 18Caserapport2026

    Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use.

    Vadner DJ, et al. · JAAD Case Reports · single patient with concurrent tanning bed use, melanotan exposure and anabolic hormone use

    Five primary melanomas in situ were diagnosed in one patient with recent melanotan exposure alongside tanning bed and anabolic hormone use. Confounding by concurrent ultraviolet exposure means causality cannot be attributed to melanotan.

    Rapporteret sikkerhedsfund. Multiple primary in situ melanomas reported in the context of melanotan exposure.

  19. 19Caserapport2026

    Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.

    Bonchev A, et al. · Life (Basel) · three-month follow-up of a patient who self-administered melanotan II for 64 days

    Brown, nearly symmetrical pigmentation appeared on the attached gingiva of both maxillary and mandibular arches, most intense anteriorly in the lower jaw. The report documents mucosal pigmentation as a consequence of unregulated self-injection.

    Rapporteret sikkerhedsfund. Oral mucosal hyperpigmentation following self-administered melanotan II.

  20. 20Caserapport2026

    Depigmented Facial and Neck Patches Following Melanotan Use in a Patient With Atopic Dermatitis and Alopecia Areata.

    Ume A, et al. · Clinical and Experimental Dermatology · single patient with atopic dermatitis and alopecia areata

    Depigmented facial and neck patches developed following melanotan use in a patient with pre-existing autoimmune and atopic disease. The report describes a pigmentary adverse outcome opposite to the intended effect.

    Rapporteret sikkerhedsfund. Depigmentation reported after melanotan use in a patient with autoimmune comorbidity.

  21. 21Caserapport2025

    Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?

    Yassin Alsabbagh A, et al. · International Journal of Oral and Maxillofacial Surgery · 22-year-old woman who used a melanotan II nasal spray for tanning

    The patient developed an anterior maxillary mass histologically confirmed as mucosal malignant melanoma, treated by surgical resection followed by immunotherapy. The authors reviewed the literature on a possible association between melanotan use and melanoma and called for awareness of serious adverse effects of melanotan II nasal spray.

    Rapporteret sikkerhedsfund. Oral mucosal malignant melanoma reported after melanotan II nasal spray use.

  22. 22Caserapport2025

    Pyoderma Gangrenosum Secondary to Melanotan.

    Dickson D, et al. · Cureus · single patient case report

    Pyoderma gangrenosum was reported as a complication attributed to melanotan use, adding a non-pigmentary inflammatory dermatosis to the documented adverse-event profile of unregulated injectable tanning peptides.

    Rapporteret sikkerhedsfund. Pyoderma gangrenosum attributed to melanotan.

  23. 23Caserapport2022· Dutch (English abstract)

    [The risks of tanning with the Barbie drug].

    Eijmael MJPM, et al. · Ned Tijdschr Geneeskd · single case, 27-year-old man with no relevant medical history presenting to the emergency department after subcutaneous self-administration of melanotan II

    The patient had sympathomimetic symptoms two hours after self-injection and was treated with lorazepam, supplemental potassium and intravenous fluid resuscitation.

    Rapporteret sikkerhedsfund. Sympathomimetic toxicity requiring emergency treatment followed melanotan II self-injection.

  24. 24Caserapport2021

    Melanotan Tanning Injection: A Rare Cause of Priapism.

    Mallory CW, et al. · Sex Med · single case, adult man presenting with acute ischaemic priapism after subcutaneous melanotan II

    The priapism did not resolve with cavernosal aspiration, irrigation and intracavernous phenylephrine and required surgical penoscrotal decompression. The authors noted only two earlier reports of priapism after melanotan II.

    Rapporteret sikkerhedsfund. Refractory ischaemic priapism requiring surgery followed melanotan II injection.

  25. 25Caserapport2020

    Melanotan II: a possible cause of renal infarction: review of the literature and case report.

    Peters B, et al. · CEN Case Rep · single case report with literature review

    The authors described a renal infarction considered most likely attributable to melanotan II and reviewed prior reports of rhabdomyolysis and renal failure, proposing thrombotic and direct renal toxic mechanisms.

    Rapporteret sikkerhedsfund. Renal infarction was reported in association with melanotan II use.

  26. 26Caserapport2019

    Melanotan-induced priapism: a hard-earned tan.

    Dreyer BA, et al. · BMJ Case Rep · melanotan (type not stated); single case, man attending a tertiary urology centre emergency department with acute priapism after abdominal subcutaneous injection of melanotan

    The priapism was diagnosed as low-flow and managed with cavernosal aspiration, irrigation and intracavernosal phenylephrine, avoiding surgical shunting. Erectile function had not recovered at 4-week follow-up.

    Rapporteret sikkerhedsfund. Low-flow priapism with erectile function not recovered at 4 weeks followed melanotan injection.

  27. 27Caserapport2014

    Melanoma associated with the use of melanotan-II.

    Hjuler KF, Lorentzen HF · Dermatology · 20-year-old woman, Fitzpatrick skin type II, 3-4 week course of melanotan II self-injection with concurrent sunbed use

    A suspicious gluteal melanocytic lesion excised three months after a course of melanotan II self-injection was histologically confirmed as cutaneous melanoma, with universally intense pigmentation of the surrounding skin. Concurrent sunbed use is an acknowledged confounder.

    Rapporteret sikkerhedsfund. Cutaneous melanoma diagnosed in temporal association with melanotan II self-injection and sunbed use.

  28. 28Caserapport2014

    Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II.

    Schulze F, et al. · Eur J Dermatol · single case reported as a letter (no abstract)

    Eruptive naevi and darkening of pre-existing naevi were reported 24 hours after a single injection of melanotan II. Further results are not available in an abstract.

    Rapporteret sikkerhedsfund. Eruptive naevi and darkening of existing naevi within 24 hours of one melanotan II injection.

  29. 29Caserapport2013

    Atypical melanocytic naevi following melanotan injection.

    Reid C, et al. · Ir Med J · melanotan (type not stated) sold online and in tanning salons as a 'tanning jab'; single case

    Multiple new atypical naevi developed within one week of melanotan injections. The authors raised the possibility that melanotan stimulates dysplastic naevi or melanoma.

    Rapporteret sikkerhedsfund. Multiple new atypical naevi within a week of melanotan tanning injections.

  30. 30Caserapport2013· Swedish

    [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described].

    Burian E, Burian E · Lakartidningen · two cases in Sweden after injection of products marketed as melanotan II (contents not analysed in the record); no abstract

    The first two Swedish cases of eruptive naevi after injection of products marketed as melanotan II were described. Results are not available in an abstract.

    Rapporteret sikkerhedsfund. Eruptive naevi after injection of products marketed as melanotan II.

  31. 31Caserapport2012

    Melanotan-associated melanoma in situ.

    Ong S, Bowling J · Australasian Journal of Dermatology · single case of melanoma in situ in a melanotan user

    The authors reported melanoma in situ associated with melanotan use and noted that injectable melanotropic peptides are unlicensed compounds with an unproven safety record sold over the internet, with prior reports of dysplastic naevi and melanoma.

    Rapporteret sikkerhedsfund. Melanoma in situ associated with unlicensed melanotropic peptide use.

  32. 32Caserapport2012

    Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.

    Nelson ME, et al. · Clin Toxicol (Phila) · single case, 39-year-old man after subcutaneous injection of internet-sourced melanotan II (identity confirmed by mass spectrometry)

    The patient developed sympathomimetic toxicity with tachycardia, agitation, mydriasis and diaphoresis, rhabdomyolysis with creatine kinase peaking at 17,773 IU/L, and acute kidney dysfunction, and required ICU care before recovering.

    Rapporteret sikkerhedsfund. Sympathomimetic toxicity, rhabdomyolysis and renal dysfunction followed a melanotan II overdose.

  33. 33Caserapport2012

    Changes of melanocytic lesions inducedby Melanotan injections and sun bed use ina teenage patient with FAMMM syndrome.

    Sivyer GW · Dermatol Pract Concept · single case, 16-year-old girl with familial atypical multiple mole melanoma (FAMMM) syndrome who self-injected Melanotan 2 and attended a UV tanning studio

    She presented with generalised tanning, multiple dark melanocytic naevi and an enlarging naevus in the left groin, and was referred because some darkened naevi were potentially malignant. Concurrent sunbed use is a confounder.

    Rapporteret sikkerhedsfund. Darkening and enlargement of naevi after melanotan II self-injection in a teenager with a familial melanoma syndrome.

  34. 34Caserapport2012· German (English abstract)

    [Dermoscopic changes in melanocytic nevi during use of melanotan II].

    Mang R, et al. · Hautarzt · single case, 24-year-old man self-injecting internet-purchased melanotan II for cosmetic reasons, naevi followed by sequential videodermoscopy before and during use

    Sequential videodermoscopy documented changes in the patient's naevi during melanotan II use, and the changes made it difficult to differentiate a naevus from a melanoma.

    Rapporteret sikkerhedsfund. Dermoscopic naevus changes during melanotan II use hampered distinction from melanoma.

  35. 35Caserapport2011· Danish (English abstract)

    [Melanotan-induced lentigines and nevi].

    Thestrup-Pedersen K, Søndergaard K · Ugeskr Laeger · melanotan (type not stated); single case, 25-year-old man who repeatedly self-injected melanotan to increase skin pigmentation

    Skin pigmentation increased markedly, existing naevi darkened, and new naevi and lentigines developed, including on the genitals. Two excised naevi showed no signs of malignant transformation.

    Rapporteret sikkerhedsfund. New and darkened naevi and lentigines, including genital lesions, after repeated melanotan self-injection.

  36. 36Caserapport2009

    Eruptive melanocytic naevi following melanotan injection.

    Cousen P, et al. · British Journal of Dermatology · case report of eruptive melanocytic naevi after melanotan injection

    This early report established the eruptive melanocytic naevus signal that has since been replicated in multiple independent case reports across several countries. The PubMed record carries no abstract.

    Rapporteret sikkerhedsfund. Eruptive melanocytic naevi following melanotan injection; the index report for this adverse-event pattern.

Begrænsninger

Hvad denne evidens ikke fastslår.

The only controlled human trials of melanotan II are two small crossover studies of 10 men each in erectile dysfunction from 1998 and 2000; there is no trial of it for tanning, no pharmacovigilance system covering it, and only one laboratory analysis of online-supplied vials (2015), which found less active peptide than labelled and unidentified impurities. The rest of the human melanotan II literature is case reports, letters and qualitative forum analyses. Because melanotan II is non-selective across melanocortin receptors, its systemic effects differ from those of the MC1R-selective approved analogues, so afamelanotide trial data cannot be used to infer melanotan II safety. Whether melanotan exposure causes melanoma is unresolved: reported cases are consistently confounded by concurrent ultraviolet and sunbed exposure, and no controlled epidemiological study exists.

Almindelige spørgsmål om forskningen.

What is Melanotan 2?

Melanotan 2 (MT-II) is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone, developed as a research tool for studying melanocortin-receptor pharmacology. It is a non-selective agonist at the MC1, MC3, MC4, and MC5 receptors.

How does it differ from PT-141 (bremelanotide)?

PT-141 is a metabolite-derived analogue of Melanotan 2 developed for MC4R selectivity. MT-II activates the wider melanocortin receptor family, whereas the PT-141 programme deliberately narrowed the receptor profile after the erectile-response findings in the MT-II crossover study.

Why is the research literature on this compound so small?

MT-II served mainly as a proof-of-concept tool compound. Once its receptor pharmacology was mapped, clinical development shifted to receptor-selective successors, so the direct MT-II literature consists of the original design papers and a handful of small early-phase trials.

Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning, og intet studie opsummeret her skal læses som en anbefaling.